Jazz Pharmaceuticals Analyst Price Targets - Benzinga

Jazz Pharmaceuticals PLC

JAZZNASDAQ

Trade with Public

Trade with Public

$244.56

0.840.35%

al cierre: Sep 2, 5:00 PM EST

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Jazz Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Jazz Pharmaceuticals (JAZZ).

Price Target Range — 9 Quarters

Analyst Consensus — 19 Analysts

17Buy

2Hold

Consensus RatingBuy# Analysts19Avg. Consensus PT$257Upside to Avg. PT+4.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 26, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$287→$300
Aug 26, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$283→$322
Aug 26, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$264→$281
Aug 26, 2026	Needham	Ami Fadia	PT Raise	Buy	$292→$310
Aug 11, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$280→$283
Aug 4, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$265→$276
Aug 4, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$254→$264
Aug 4, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$275→$300
Aug 4, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$301→$310
Aug 4, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$285→$300
Aug 4, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$245→$280
Aug 4, 2026	Needham	Ami Fadia	PT Raise	Buy	$282→$292
Aug 4, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$260→$270
Aug 4, 2026	Baird	Joel Beatty	PT Raise	Outperform	$252→$280
Jul 20, 2026	Needham	Ami Fadia	PT Raise	Buy	$255→$282
Jul 17, 2026	Canaccord Genuity	Gary Nachman	Initiate	Buy	$290
Jul 14, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$265→$285
Jul 14, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$253→$260
Jul 9, 2026	Deutsche Bank	Gregg Gilbert	PT Raise	Buy	$250→$270
Jul 7, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$256→$254

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.

Benzinga Newsdesk

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.

Avi Kapoor

PRO
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $281

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $264 to $281.

Benzinga Newsdesk

MongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT target, BTIG cut $DKS target, HC raised $ZYME target, Needham increased $JAZZ target, Bernstein cut $MSTR target, Barclays raised $MDB target, UBS raised $SMTC target.

Avi Kapoor

PRO
Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $310

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $292 to $310.

Benzinga Newsdesk